PROMETIC (1)

symetry121

(0)

56318 Reads | 19 Comments | 3 People call this a favourite

• Add blog to favourites

• T.PLI: 2014 outlook

  
  
  357 Reads | 0 Comments | February 4, 2014
  
  

  2014 OUTLOOK ( what we know ) +++ " ??? " Looking ahead, we expect up to 5 IND's filings in 2014 : 1st to be plasminogen in H1, followed by Alpha-1-antitrypsin early H2, plus 3 more undisclosed high value plasma Rx ( 2 from the Nantpharma deal ) ... The following of the phase I on PBI-4050 which results are imminent then the start of the next phase also in H1 ( most likely in the...

  ---

• T.PLI: 2014 outlook

  
  
  221 Reads | 0 Comments | February 4, 2014
  
  

  2014 OUTLOOK ( what we know ) +++ " ??? " Looking ahead, we expect up to 5 IND's filings in 2014 : 1st to be plasminogen in H1, followed by Alpha-1-antitrypsin early H2, plus 3 more undisclosed high value plasma Rx ( 2 from the Nantpharma deal ) ... The following of the phase I on PBI-4050 which results are imminent then the start of the next phase also in H1 ( most likely in the fibrosis...

  ---

• T.PLI:Paradigm price target:2.25$

  
  
  296 Reads | 0 Comments | January 30, 2014
  
  

  1/23/2014 Paradigm Capital Boost Price Target Buy C$1.35 -> C$2.25 http://www.analystratings.net/stocks/TSE/PLI/ Read more at http://www.stockhouse.com/companies/bullboard/t.pli/prometic-life-sciences-inc#etO7Y625aUg1Udok.99

  ---

• T.PLI:NR:Key Plasma Protein Manufacturing Milestone

  
  
  312 Reads | 0 Comments | January 22, 2014
  
  

  ProMetic Achieves Key Plasma Protein Manufacturing Milestone - Milestone triggers $1.0 million payment LAVAL, QUEBEC--(Marketwired - Jan. 22, 2014) - ProMetic Life Sciences Inc. (TSX:PLI)(OTCQX:PFSCF), ("ProMetic" or the "Corporation") announced today the achievement of the second manufacturing milestone related to its strategic agreement ("Agreement") with...

  ---

• T.PLI: Hybridan says sp worth 1.81$ today...

  
  
  361 Reads | 0 Comments | January 21, 2014
  
  

  Hybridan's new $1.81 target! 2014: Moving up a gear Despite the three-fold increase in the share price in the past year, we believe the shares could easily double this year. 2013 was a transformational year, with several deals and milestones and a few positive surprises, particularly from the Therapeutics division. We expect no less in 2014 although we expect the structure of any...

  ---

• T.PLI: Hybridan says sp worth 1.81$

  
  
  353 Reads | 0 Comments | January 20, 2014
  
  

  Hybridan's new $1.81 target! 2014: Moving up a gear Despite the three-fold increase in the share price in the past year, we believe the shares could easily double this year. 2013 was a transformational year, with several deals and milestones and a few positive surprises, particularly from the Therapeutics division. We expect no less in 2014 although we expect the structure of any...

  ---

• T.PLI: interesting info from IR at PLI...

  
  
  294 Reads | 0 Comments | January 19, 2014
  
  

  RE:Reply to short term trading - being caught with your pants d I agree with you Agalea. That's also why I'm keeping 100% of my position. If US funds are starting to buy like I think , this could bring us near $1.50 very quickly ... So here's from IR at ProMetic on last week in San Fransisco :  A very busy and great overall conference indeed. It is pretty...

  ---

• T.PLI:CEO questions and answers

  
  
  313 Reads | 0 Comments | December 17, 2013
  
  

  Interview: Pierre Laurin, President and CEO, ProMetic Life Sciences Inc. Canada 27.06.2013 / Pharmaboardroom Related Top 50 pharma companies in 2012, by global sales 13.12.2013 Top 50 biotech companies in 2012 by global sales 13.12.2013 Interview: Deborah M. Brown, President, Merck Serono, Canada 05.12.2013 Mr. Pierre Laurin...

  ---